Indivior Pharmaceuticals, Inc. Research And Development Expense

Quick Answer

Indivior Pharmaceuticals, Inc. reported Research And Development Expense of $106.00 million for the year ending 2023.

  • Indivior Pharmaceuticals, Inc. showed an increase of +47.2% in Research And Development Expense from 2022 to 2023.
  • This data is from Indivior Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2024.
  • XBRL data for this metric is available from 2021 to 2023 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2021 to 2023), Indivior Pharmaceuticals, Inc.'s Research And Development Expense has grown by 103.8%.
  • Historical annual values: Fiscal year 2023: $106.00 million | Fiscal year 2022: $72.00 million | Fiscal year 2021: $52.00 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: